SILAN, C. Et Al. 2012. The prevalence of VKORC1 1639 G > A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population. MOLECULAR BIOLOGY REPORTS , vol.39, no.12 , 11017-11022.

SILAN, C., DOĞAN, Ö. T., Silan, F., Kukulguven, F. M., AŞGÜN, H. F., Ozdemir, S., ... ULUDAĞ, A.(2012). The prevalence of VKORC1 1639 G > A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population. MOLECULAR BIOLOGY REPORTS , vol.39, no.12, 11017-11022.

SILAN, COŞKUN Et Al. "The prevalence of VKORC1 1639 G > A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population," MOLECULAR BIOLOGY REPORTS , vol.39, no.12, 11017-11022, 2012

SILAN, COŞKUN Et Al. "The prevalence of VKORC1 1639 G > A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population." MOLECULAR BIOLOGY REPORTS , vol.39, no.12, pp.11017-11022, 2012

SILAN, C. Et Al. (2012) . "The prevalence of VKORC1 1639 G > A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population." MOLECULAR BIOLOGY REPORTS , vol.39, no.12, pp.11017-11022.

@article{article, author={COŞKUN SILAN Et Al. }, title={The prevalence of VKORC1 1639 G > A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population}, journal={MOLECULAR BIOLOGY REPORTS}, year=2012, pages={11017-11022} }